Enbrel, Etanercept News

Global Autoimmune Disease Therapeutics Market To Reach $50B By 2015, According To A New Report By Global Industry Analysts July 3, 2009 GIA announces the release of a comprehensive global report on Autoimmune Disease Therapeutics market.

What's the difference between rheumatoid and osteoarthritis? When you think of arthritis, you probably picture joints that start aching as you get older and worsen thanks to excess weight or lack of physical activity .

Evotec AG today announced the successful completion of the first Phase I study with its P2X7 receptor antagonist EVT 401.

Since 2002, David and Tom Gardner have returned 30.96% while the S&P 500 returned -10.28%. Try Stock Advisor free for 30 days.

Treatment with anti-tumor necrosis factor agents is recognized as a risk factor for tuberculosis in patients with immune-mediated inflammatory diseases such as rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, psoriatic arthritis and psoriasis.

Abbott Laboratories plans to appeal a jury's $1.67 billion patent infringement ruling in a case involving two blockbuster drugs that treat rheumatoid arthritis and other immune disorders.

Main Category: Arthritis / Rheumatology Also Included In: Clinical Trials / Drug Trials Article Date: 29 Jun 2009 An article published Online First and in this week's edition of reports information about Golimumab, a new tumour necrosis factor- inhibitor.

Golimumab, a new tumour necrosis factor-I inhibitor reduces the signs and symptoms of rheumatoid arthritis in patients who have previously received any other TNF-I inhibitor, and might be a good option for patients who have inadequate responses to one or two other TNF-I inhibitors, finds an Article published Online first and in this week's edition ...

Since 2002, David and Tom Gardner have returned 31.35% while the S&P 500 returned -10.29%. Try Stock Advisor free for 30 days.

I well remember the day I ceded control of my spinal column. Years ago, I bent over at the waist with my daughter in one arm to pick up my house keys.

Rigel Pharmaceuticals Inc's experimental oral treatment for rheumatoid arthritis would hold its own against a rival drug in development at Pfizer and has the potential to be a multi-billion dollar business, a top company official said.

Are there alternatives to glucosamine-chondroitin therapy for arthritis? IN Malaysia, an estimated 60% of the population will have some form of arthritis by the age of 60, particularly osteoarthritis.

The effectiveness to treat sciatica of an existing medication for arthritis and psoriasis is currently being evaluated in clinical trials in Melbourne and Adelaide, Australia.

Main Category: Arthritis / Rheumatology Also Included In: Pharma Industry / Biotech Industry Proteolix, Inc.

Early Combination Of Enbrel And Methotrexate Halts Radiographic Progression In 90% Of Patients During Second Year Of The COMET Study New data presented this week during the European League Against Rheumatism Annual Meeting in Copenhagen demonstrated that sustained combination therapy was consistently superior to continuous methotrexate monotherapy ...

Main Category: Arthritis / Rheumatology Also Included In: Pediatrics / Children's Health Article Date: 15 Jun 2009 Three new studies have individually shown the anti-TNF therapy etanercept to be effective, with a good safety profile, in children under four years of age with juvenile idiopathic arthritis , and associated with improved Health-Related ...

Wyeth Presents New Analyses Of Data From Three Studies Of ENBREL At The European League Against Rheumatism Annual Meeting Analyses of data from three studies provide insight into the use of ENBREL in the treatment of three conditions for which ENBREL is indicated: moderate-to-severe rheumatoid arthritis , psoriatic arthritis and ankylosing ...

Officials at the Federal Trade Commission say the 12- to 14-year patent-protection period given to biologic medications is too long to "promote innovation" in the development of these types of drugs.

Copenhagen, Denmark, Friday 12 June 2009: Three new studies have individually shown the anti-TNF therapy etanercept to be effective, with a good safety profile, in children under four years of age with juvenile idiopathic arthritis , and associated with improved Health-Related Quality of Life in a substantial proportion of children with JIA.

New Analysis Shows Efficacy Of SIMPONI In Anti-TNF Experienced Rheumatoid Arthritis Patients Main Category: Arthritis / Rheumatology Also Included In: Pharma Industry / Biotech Industry A new analysis demonstrated that a greater proportion of patients with moderately to severely active rheumatoid arthritis who had prior treatment with anti-tumor ...